Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
nasal spray
Pharma
J&J builds case for Spravato in tough-to-treat depression
Johnson & Johnson’s esketamine nasal spray continues to build a body of evidence showing it can go toe-to-toe with tricky-to-treat depression.
Fraiser Kansteiner
Nov 23, 2022 10:05am
FDA accepts ARS' filing for nasal spray EpiPen rival for review
Oct 25, 2022 10:27am
Bryn advances anaphylaxis spray after completing pivotal trial
Sep 19, 2022 7:00am
SaNOtize bags $24M to fund phase 3 trial of COVID-19 nasal spray
Aug 30, 2022 9:55am
ARS inks reverse merger to get epinephrine nasal spray to market
Jul 26, 2022 10:22am
J&J program adds Ena's infectious disease nasal spray to roster
May 16, 2022 11:41am
